Oncolys BioPharma Inc. (4588.T)
JPY 530.0
(0.38%)
JPY 530.0
(0.38%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -1.92 Billion JPY | -60.23% |
| 2022 | -1.2 Billion JPY | 17.19% |
| 2021 | -1.45 Billion JPY | 13.14% |
| 2020 | -1.67 Billion JPY | -227.42% |
| 2019 | -511.46 Million JPY | 59.0% |
| 2018 | -1.24 Billion JPY | -15.69% |
| 2017 | -1.07 Billion JPY | -25.2% |
| 2016 | -861.31 Million JPY | 9.49% |
| 2015 | -951.57 Million JPY | -14.96% |
| 2014 | -827.74 Million JPY | -24.39% |
| 2013 | -665.46 Million JPY | -372.11% |
| 2012 | -140.95 Million JPY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -378.87 Million JPY | 38.79% |
| 2024 Q2 | -414.49 Million JPY | -9.4% |
| 2023 Q4 | -618.94 Million JPY | -50.94% |
| 2023 FY | -1.92 Billion JPY | -60.23% |
| 2023 Q1 | -325.57 Million JPY | -21.88% |
| 2023 Q2 | -575.41 Million JPY | -76.74% |
| 2023 Q3 | -410.04 Million JPY | 28.74% |
| 2022 FY | -1.2 Billion JPY | 17.19% |
| 2022 Q2 | -274.15 Million JPY | 28.75% |
| 2022 Q1 | -384.74 Million JPY | 21.62% |
| 2022 Q4 | -267.12 Million JPY | 4.08% |
| 2022 Q3 | -278.48 Million JPY | -1.58% |
| 2021 Q3 | -330.05 Million JPY | -16.16% |
| 2021 Q4 | -490.9 Million JPY | -48.74% |
| 2021 Q1 | -349.45 Million JPY | 31.09% |
| 2021 Q2 | -284.14 Million JPY | 18.69% |
| 2021 FY | -1.45 Billion JPY | 13.14% |
| 2020 Q3 | -507.21 Million JPY | -36.13% |
| 2020 Q4 | -507.14 Million JPY | 0.01% |
| 2020 FY | -1.67 Billion JPY | -227.42% |
| 2020 Q2 | -372.6 Million JPY | -29.51% |
| 2020 Q1 | -287.69 Million JPY | -480.92% |
| 2019 FY | -511.46 Million JPY | 59.0% |
| 2019 Q1 | -364.58 Million JPY | -9.76% |
| 2019 Q3 | -311.76 Million JPY | -448.88% |
| 2019 Q2 | 89.36 Million JPY | 124.51% |
| 2019 Q4 | 75.52 Million JPY | 124.22% |
| 2018 Q3 | -271.68 Million JPY | 20.34% |
| 2018 Q4 | -332.15 Million JPY | -22.26% |
| 2018 Q2 | -341.05 Million JPY | -12.69% |
| 2018 FY | -1.24 Billion JPY | -15.69% |
| 2018 Q1 | -302.66 Million JPY | 2.36% |
| 2017 Q4 | -309.97 Million JPY | -19.79% |
| 2017 FY | -1.07 Billion JPY | -25.2% |
| 2017 Q1 | -235.11 Million JPY | -29.36% |
| 2017 Q2 | -274.54 Million JPY | -16.77% |
| 2017 Q3 | -258.75 Million JPY | 5.75% |
| 2016 Q4 | -181.75 Million JPY | 32.42% |
| 2016 Q3 | -268.96 Million JPY | -17.69% |
| 2016 Q1 | -182.06 Million JPY | 27.98% |
| 2016 FY | -861.31 Million JPY | 9.49% |
| 2016 Q2 | -228.53 Million JPY | -25.53% |
| 2015 Q1 | -304.2 Million JPY | 0.1% |
| 2015 FY | -951.57 Million JPY | -14.96% |
| 2015 Q4 | -252.8 Million JPY | -30.72% |
| 2015 Q3 | -193.39 Million JPY | 3.86% |
| 2015 Q2 | -201.16 Million JPY | 33.87% |
| 2014 FY | -827.74 Million JPY | -24.39% |
| 2014 Q2 | -189.69 Million JPY | -12.51% |
| 2014 Q3 | -164.92 Million JPY | 13.06% |
| 2014 Q4 | -304.52 Million JPY | -84.64% |
| 2014 Q1 | -168.59 Million JPY | 34.57% |
| 2013 FY | -665.46 Million JPY | -372.11% |
| 2013 Q4 | -257.67 Million JPY | 0.0% |
| 2012 FY | -140.95 Million JPY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 596.82 Million JPY | 423.377% |
| PRISM BioLab Co.,LTD | -496.86 Million JPY | -288.43% |
| GNI Group Ltd. | 13.1 Billion JPY | 114.723% |
| Linical Co., Ltd. | 725.72 Million JPY | 365.939% |
| Trans Genic Inc. | 89.43 Million JPY | 2257.952% |
| MEDINET Co., Ltd. | -1.42 Billion JPY | -35.347% |
| Soiken Holdings Inc. | -610 Million JPY | -216.388% |
| Cytori Cell Research Institute, Inc. | -772.74 Million JPY | -149.758% |
| AnGes, Inc. | -11.96 Billion JPY | 83.873% |
| OncoTherapy Science, Inc. | -1.12 Billion JPY | -72.197% |
| Nxera Pharma Co., Ltd. | -9.52 Billion JPY | 79.74% |
| Immuno-Biological Laboratories Co., Ltd. | 104.29 Million JPY | 1950.436% |
| NanoCarrier Co., Ltd. | -864.41 Million JPY | -123.271% |
| Carna Biosciences, Inc. | -1.11 Billion JPY | -72.786% |
| CanBas Co., Ltd. | -1.26 Billion JPY | -52.931% |
| D. Western Therapeutics Institute, Inc. | -798.55 Million JPY | -141.684% |
| RaQualia Pharma Inc. | -337.36 Million JPY | -472.077% |
| Chiome Bioscience Inc. | -1.2 Billion JPY | -60.142% |
| Kidswell Bio Corporation | -1.33 Billion JPY | -44.504% |
| PeptiDream Inc. | 6.77 Billion JPY | 128.495% |
| Ribomic Inc. | -1.11 Billion JPY | -72.908% |
| SanBio Company Limited | -4.53 Billion JPY | 57.48% |
| Healios K.K. | -3.37 Billion JPY | 42.883% |
| BrightPath Biotherapeutics Co., Ltd. | -1.15 Billion JPY | -67.087% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -1.39 Billion JPY | -38.498% |
| Delta-Fly Pharma, Inc. | -1.4 Billion JPY | -37.561% |
| StemRIM | -2.07 Billion JPY | 7.033% |
| CellSource Co., Ltd. | 1.22 Billion JPY | 258.001% |
| FunPep Company Limited | -994 Million JPY | -94.164% |
| Kringle Pharma, Inc. | -888.76 Million JPY | -117.154% |
| Stella Pharma Corporation | -760.3 Million JPY | -153.845% |
| TMS Co., Ltd. | -943.25 Million JPY | -104.61% |
| Noile-Immune Biotech Inc. | -775.39 Million JPY | -148.905% |
| Cuorips Inc. | -588.48 Million JPY | -227.957% |
| K Pharma,Inc. | 366.05 Million JPY | 627.236% |
| Takara Bio Inc. | 3 Billion JPY | 164.269% |
| ReproCELL Incorporated | -409.29 Million JPY | -371.541% |
| PhoenixBio Co., Ltd. | 11.06 Million JPY | 17545.413% |
| StemCell Institute Inc. | 413.75 Million JPY | 566.452% |
| Japan Tissue Engineering Co., Ltd. | 144.5 Million JPY | 1435.566% |
| CellSeed Inc. | -697.77 Million JPY | -176.591% |